Default company panoramic image

Anagenesis Biotechnologies

ANAGENESIS created a unique technology platform for the development of new therapeutic strategies for muscle, skeleton and skin disorders

  • Stage Product In Development
  • Industry Biotechnology
  • Location Strasbourg, Alsace, France
  • Currency EUR
  • Founded April 2011
  • Employees 0

Company Summary

ANAGENESIS allows for the first time to produce in vitro unlimited amounts of healthy and diseased human cells of the muscular, skeletal and skin lineages. They will revolutionize the therapeutic strategies for a wide range of human diseases by providing unique in vitro tools for high throughput screening and identifying new pharmacological agents, but will also constitute a unique source of biological material for cell & gene therapy strategies.


  • Default avatar
    Christopher Henderson, PhD
    Co-Founder & Scientific Board Member

    Professor of regenerative Biology at Columbia University, NY. Director of the Columbia Stem Cell Initiative. He is a cofounder of the Biotech company Trophos.

  • Default avatar
    Olivier Pourquié, PhD
    Founder & Scientific Board Member

    Currently Professor at the Strasbourg ˝Faculté de Médecine˝ and group leader at the ˝Institut de Biologie Moléculaire et Cellulaire˝ (IGBMC) in Illkirch. For the past 15 years, Olivier Pourquié’s group has been studying the differentiation of muscle, skeletal and dermal precursor cells in the embryo and he is an internationally recognized leader in the field of musculoskeletal axis development. He is a cofounder of the Biotech company Trophos.

  • Default avatar
    Thierry Noel
    CEO and Co-Founder

    MBA at London Business School, graduate of the Institut National Agronomique Paris-Grignon Thierry Noel started his career in the group ˝Suez Environnement˝ where he held executive, operational and strategic positions for 15 years. In 2007, he created his own consulting company, Amane advisors, specialized in strategy, external and internal growth, and project or technology development in the field of environment and renewable energy production.

  • Default avatar
    Marie Knockaert, PhD

    PhD in the field of anti-cancer drug development.
    After several collaborations with pharmaceutical companies during her PhD, she has joined the group of Professor Ali Brivanlou at The Rockefeller University in New York to refine her expertise in human ES and iPS cells and learn about scientific projects' management.
    She joined O. Pourquié's group in 2009 to coordinate the large strategic grant from the French Muscular Dystrophy Association (AFM

  • Default avatar
    Jean-Yves Bonnefoy, PhD
    Board Member

    VP R&D Transgene

  • Default avatar
    Jérôme Chal, PhD

    PhD and postdoctoral training in Olivier Pourquié’s laboratory at the Stowers Institute for Medical Research on the differentiation of muscle, skeletal and dermal precursor cells in the embryo.
    In 2009, he returned to France with Pr. Pourquié. He is an expert in stem cell biology and he has supervised the development of the technology developed by ANAGENESIS.

  • Default avatar
    Nicolas Carboni
    Board Member

    President of SATT Alsace (technology transfer office)


  • Default avatar
    Luc BARNY
    Default avatar
    Romain GUEDON